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Abstract
Background: In modern cancer medicine, morphological magnetic resonance imaging (MRI) is routinely used in
diagnostics, treatment planning and assessment of therapeutic efficacy. During the past decade, functional imaging
techniques like diffusion-weighted (DW) MRI and dynamic contrast-enhanced (DCE) MRI have increasingly been
included into imaging protocols, allowing extraction of intratumoral information of underlying vascular, molecular
and physiological mechanisms, not available in morphological images. Separately, pre-treatment and early changes
in functional parameters obtained from DWMRI and DCEMRI have shown potential in predicting therapy response.
We hypothesized that the combination of several functional parameters increased the predictive power.
Methods: We challenged this hypothesis by using an artificial neural network (ANN) approach, exploiting nonlinear
relationships between individual variables, which is particularly suitable in treatment response prediction involving
complex cancer data. A clinical scenario was elicited by using 32 mice with human prostate carcinoma xenografts
receiving combinations of androgen-deprivation therapy and/or radiotherapy. Pre-radiation and on days 1 and 9
following radiation three repeated DWMRI and DCEMRI acquisitions enabled derivation of the apparent diffusion
coefficient (ADC) and the vascular biomarker K
trans, which together with tumor volumes and the established
biomarker prostate-specific antigen (PSA), were used as inputs to a back propagation neural network,
independently and combined, in order to explore their feasibility of predicting individual treatment response
measured as 30 days post-RT tumor volumes.
Results: ADC, volumes and PSA as inputs to the model revealed a correlation coefficient of 0.54 (p < 0.001)
between predicted and measured treatment response, while K
trans, volumes and PSA gave a correlation coefficient
of 0.66 (p < 0.001). The combination of all parameters (ADC, K
trans, volumes, PSA) successfully predicted treatment
response with a correlation coefficient of 0.85 (p < 0.001).
Conclusions: We have in a preclinical investigation showed that the combination of early changes in several
functional MRI parameters provides additional information about therapy response. If such an approach could be
clinically validated, it may become a tool to help identifying non-responding patients early in treatment, allowing
these patients to be considered for alternative treatment strategies, and, thus, providing a contribution to the
development of individualized cancer therapy.
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Prostate cancer (PCa) is a disease characterized by bio-
logically heterogeneous behaviour. Treatment of PCa is
controversial, with no established consensus on screen-
ing or diagnostic tests for pre-treatment evaluation of
PCa aggressiveness [1,2]. Consequently, the ability to
differentiate between low-risk and high-risk patients
and the need for and appropriateness of treatment at
any stage of the disease, remains a difficult issue.
Whereas low-risk PCa patients are faced with problems
associated with over-treatment, high-risk PCa patients
might be suffering from under-treatment and high fre-
quency of recurrence. Thus, PCa represents a disease
in which early prediction of ultimate therapeutic effi-
cacy is critical, but so far has been challenging to
achieve.
Prediction of individual therapy response is critically
dependent on the ability to quantify tumor heterogene-
ity and heterogeneous response of tumors with other-
wise identical clinical prognostic factors. Established,
non-invasive methods that effectively evaluate the het-
erogeneous therapy responses are elusive in clinical
practice. Radiological response to treatment is most
commonly quantified by measuring the tumor dia-
meter in one or two directions. However, functional
magnetic resonance imaging (MRI) techniques, like dif-
fusion-weighted (DW) MRI and dynamic contrast-
enhanced (DCE) MRI, are promising and have opened
for repeated in vivo assessment of biomarkers from
underlying vascular, molecular and physiological pro-
cesses in individual tumors. DWMRI depicts the local
microstructural characteristics of water diffusion, can
be quantified by calculating the apparent diffusion
coefficient (ADC), and enables detection of micro-
scopic changes in tissue structure and physiology [3,4].
Further, by tracking the entrance of a diffusible con-
trast agent from the tumor vasculature and into the
extravascular, extracellular space, DCEMRI allows
deduction of the vascular biomarker K
trans [5], which
may be of particular importance in clinical response
monitoring of increased or inhibited angiogenesis.
K
trans has also been shown to reflect tumor oxygena-
tion status, which is an important factor for successful
radiotherapy (RT) outcome [6]. Alterations in func-
tional imaging parameters have been shown to precede
tumor volume reductions, enabling identification of
good and poor responders at an early time-point, and
thus, facilitation of individualized treatment schedules
[6-13]. These functional MRI techniques are now
increasingly becoming in routine use in many radiolo-
gical departments, thus, the approach presented in the
current study suggests a further use of these data, by
exploiting them in prediction modeling together with
standard clinical parameters.
Medical artificial intelligence is a methodology that
potentially can support clinicians in deciding correct
diagnosis, making therapeutic decisions and predicting
therapeutic outcome [14,15]. Artificial neural networks
(ANNs) are attractive analytical tools in medicine due to
their ability to learn from historical examples, analyze
non-linear data and being able to generalize a model to
independent data. ANNs are inspired by the biological
nervous system and consist of interconnected processes
utilizing parallel computations, analogous to the biologi-
cal neurons being the brain’s processing units. There are
numerous ANN methods, however, this study concen-
trates on the back propagation neural network (BPNN)
approach. This method was originally described by
Rumelhart et al [16], and has become one of the most
popular ANN algorithms in medicine, due to the
demonstration of high prediction outcomes in a range
of medical applications, which also inspired us to imple-
ment and test this approach. The BPNN architecture
consists of many identical nodes, or neurons, mainly
consisting of nonlinear activation functions. The nodes
are interconnected by weights, representing the inter-
neuron synapses in the brain. Further, the BPNN archi-
tecture is divided into three layers; input, hidden and
output layers. The input layer feeds information into the
network, while the nodes in the hidden layers and out-
put layers process the information. The nodes in the
hidden layer do not have predefined initial values, but
do allow complex relationships between input and out-
put nodes to develop. The training process consists of
forward and backward propagation of signals. In the for-
ward training process, input data are forwardly propa-
gated in the network while known output parameters
are kept in the output nodes to compare the results
generated by the network. In the back propagation
training phase, the respective differences (errors) are
used to change the interconnecting weights by using a
gradient learning algorithm by back propagating the
errors [16].
ANNs have previously been applied on PCa patient
data in order to predict treatment outcome based on
clinical parameters like tumor volume, prostate-specific
antigen (PSA), the primary and regional nodal extent of
t h et u m o ra n dt h ea b s e n c eo rp r e s e n c eo fm e t a s t a s e s
(TNM classification), biopsyG l e a s o ns c o r ea n da g ea s
input parameters [14,17-21]. In the study by Gulliford et
al [17], volume, PSA and tumor stage were used as
inputs. Although the resultsf r o mt h i ss t u d yu n v e i l e da
predictive potential, both the sensitivity and the specifi-
city were low (sensitivity; 66.8 - 70.2%, specificity; 52.7 -
64.2%). Further, Stephan et al [21] performed a study
where PSA was used as input to an ANN approach in
order to investigate whether such a model could differ-
entiate between PCa and benign prostatic disease. Also
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62.1% and 45.5%, for 90% and 95% sensitivity, respec-
tively. We hypothesize that the addition of functional
magnetic resonance imaging (MRI) parameters into a
prediction model might provide valuable intratumoral
information that, in addition to the established clinical
parameters, will contribute to improve the prediction of
therapeutic efficacy.
To explore whether the combined use of pre-treat-
ment and early therapy-induced changes in functional
MRI parameters increases the prediction of therapeutic
response, we elicited a clinical scenario by using human,
androgen-sensitive prostate carcinoma xenografts receiv-
ing RT and/or androgen-deprivation therapy (ADT).
Functional MRI parameters were derived after three
repeated DWMRI and DCEMRI sessions, and together
with volumes and PSA measurements, these parameters
were independently and combined used as inputs to a
BPNN in order to explore their feasibility of predicting
treatment response measured as 30 days post-RT tumor
volumes.
Methods
A schematic synopsis of the experiment is provided in
Figure 1.
Animals, xenografts and treatment
Male, sexually mature BALB/c nude mice (30 - 35 g, 6 -
8 weeks old) were subcutaneously (s.c.) implanted with
~( 2×2×2 )m m
3 tumor tissue from the human,
androgen-sensitive CWR22 xenograft. Procedures for
implantation of xenografts are previously described [22].
All animal experiments were performed according to
protocols approved by the animal care and use
committee.
Animals were included in the experiment when their
shortest tumor diameter reached 8 mm. Androgen-
deprived CWR22 xenografts (CWR22-cas) were
obtained by surgical castration of animals bearing
CWR22 xenografts at a shortest tumor diameter of 13
mm; the animals were included in the experiment when
CWR22-cas xenografts had regressed to a shortest dia-
meter of 8 mm. The time from castration to inclusion
was 36 ± 4 days. Totally 32 animals (4 groups of 8 ani-
mals) were used; CWR22 control, CWR22 irradiation,
CWR22-cas control and CWR22-cas irradiation. At
inclusion, animals were subjected to a pre-treatment
(day 0) MRI before tumors in the irradiation groups
received a single-dose of 15 Gy from a
60Co source
(Mobaltron 80, TEM Instruments, Crawley, UK) with a
dose rate of 0.8 Gy/min. At day 1 and day 9 repeated
MRIs were performed of all animals.
Anesthesia was provided as s.c. injections of a mixture
of 2.4 mg/ml tiletamine and 2.4 mg/ml zolazepam
(Zoletil vet, Virbac Laboratories, Carros, France), 3.8
mg/ml xylazine (Narcoxyl vet, Roche, Basel, Switzer-
land), and 0.1 mg/ml butorphanol (Torbugesic, Fort
Dodge Laboratories, Fort Dodge, IA), diluted 1:5 in ster-
ile water. A dose of 50 μl/10 g was given prior to irra-
diation and 75 μl/10 g before MRI and castration.
Castrated animals received analgesia as 0.1 mg/kg s.c.
injections of buprenorphine (Temgesic; Schering-Plough,
Brussels, Belgium).
MRI acquisition and analysis
MRI was acquired at day 0 (pre-RT), day 1 and day 9,
using a 1.5 T GE Signal LS scanner (GE Medical Sys-
tems, Milwaukee, WI). Animals were imaged using an
MRI mouse coil [23], while the temperature was main-
tained at 38°C. First, the tumor was localized using axial
fast spin-echo (FSE) T2-weighted (T2W) images (echo
time (TEeff) = 85 ms, repetition time (TR) = 4000 ms,
echo train length (ETL) = 16, image matrix (IM) = 256
× 256, field-of-view (FOV) = 4 cm, slice thickness (ST)
= 2 mm). Second, diffusion-weighted images (single shot
FSE; TEeff = 78.8 ms; TR = 5000 ms; FOV = 14 cm; IM
= 128 × 128; ST = 2 mm; interslice gap = 1 mm; b-
values = 0 and 100 s/mm
2)w e r ea c q u i r e dw i t ht h ef o l -
lowing x, y, and z directions; [1 0 1], [-1 0 1], [0 1 1], [0
1 -1], [1 1 0] and [-1 1 0]. An axial FSE T2W sequence
with identical FOV as the DWMRI was obtained for
post-processing image analysis purposes. Third, the
DCEMRI acquisitions were obtained as described
Ktrans ADC
Tumor volumes
Prostate-specific
antigen
Functional MRI
Day 0
Day 1
Day 9
Artificial
neural
network
Predicted
therapy
response
(V30)
Measured
therapy
response
(V30)
32 tumors 
Figure 1 Schematic synopsis of the study. Androgen-sensitive
prostate carcinoma xenografts received combinations of androgen-
deprivation therapy (ADT) and/or radiotherapy (RT) and were
subjected functional magnetic resonance imaging (MRI) pre-
treatment and 1 and 9 days after onset of treatment. Together with
standard clinical parameters (prostate-specific antigen (PSA), tumor
volumes) the functional MRI parameters reflecting structural
composition (apparent diffusion coefficient (ADC)) and
vascularization (K
trans) were used as inputs in an artificial neural
network to elucidate how these functional MRI parameters
independently and combined affected the prediction of therapy
response, as measured by the 30 days post-RT tumor volumes (V30).
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with saline-diluted Gd-DTPA (Magnevist
®, Schering,
Berlin, Germany) was inserted into the tail vein.
Dynamic T1-weighted (T1W) imaging was acquired by
performing 20 minutes of dynamic fast spoiled gradient-
recalled (FSPGR) imaging after the initial 5 pre-contrast
images and the 3 seconds injection of the contrast
agent. Time resolution was 12 seconds and the voxel
size was 0.23 × 0.47 × 2 mm
3. Proton density images
were acquired prior to and after DCEMRI to allow
quantification of the concentration of Gd-DTPA [24].
The vascular input function (VIF) needed in quantitative
post-processing image analysis was VIF = 3.57 ± 0.34
mM (exp((-0.025 ± 0.005 s
-1)t)) + 1.45 ± 0.15 mM (exp
((-0.0074 ± 0.0036 s
-1)t)) (22).
Post-processing DWMRI analysis was performed in
nICE (Nordic NeuroLab, Bergen, Norway). Isotropic
ADC maps were calculated voxel-wise using a mono-
exponential approach, allowing determination of mean
tumor ADCs after transferring tumor region-of-interests
(ROIs) delineated in T2W MR images to the ADC
maps. DCEMRI analysis was executed in IDL (Interac-
tive Data Language v6.2, Research Systems Inc., Boulder,
CO). ROIs were traced in post-contrast T1W images,
before contrast enhancement curves from individual
voxels were fitted to the kinetic model of Tofts [5],
allowing voxel-wise and mean tumor estimation of the
vascular biomarker K
trans (s
-1).
PSA
Blood samples from all animals at days 0, 1 and 9 were
obtained and allowed to coagulate before being centri-
fuged and stored at -80°C until analysis. Free and total
PSA were assayed by the fluoroimmunonometric Auto-
DELFIA ProStatus™ PSA Free/Total kit (PerkinElmer
Life and Analytical Sciences, Wallac Oy, Turku,
Finland).
Treatment response monitoring
From the day of implantation until day 30 post-irra-
diation, tumor volumes were estimated from caliper
measurements by using the formula (length × length
×w i d t h ) / 2 ,w i t hlength being the longest diameter
across the tumor and width the corresponding
perpendicular.
ANN simulations
Tumor volumes (V), PSA, ADC and K
trans acquired pre-
treatment and early in treatment course were normal-
ized to the individual baseline (day 0) measurement
(Figure 2) and used as inputs to a BPNN to explore
whether these parameters could predict treatment
response, as measured by individual tumor volumes 30
days post-irradiation (V30). Additionally, four categorical
(binary encoded) variables representing treatment
groups were used in all simulations. The BPNN repeat-
edly adjusted the weights of the network and the thresh-
old of each neuron according to a criterion that the cost
function minimized. The cost function was a root mean
squared error (RMSE) between the target outputs and
the actual outputs of the network. The two steps of the
learning process included:
a) Forward propagation. The value of the calculated
output, yj, was compared to the actual output, Oj,
before the output differences were inserted into the
error function E defined as:
E =
1
2
M 
i=1
N 
j=1
(Oij − yij)
2
where M is the total number of tumor response pat-
terns given as input to the network, N is the total num-
ber of output nodes of the network, and j as p e c i f i c
output node, given a specific pattern i into the network.
b) Backward propagation. The error E from equation
above was back propagated by updating the weights,
wij, using scaled conjugate gradient descents:
 wij
new =  wij
old −
∂E
∂wij
η
where h (0 <h < 1) controlled the learning rate of the
algorithm. The learning process continued until E con-
verged to a predefined value or until the maximum
number of epochs was reached. An epoch is a single
pass of the data through the ne t w o r k ,i . e .t h ed i f f e r e n t
tumor response patterns (V, PSA, ADC and/or K
trans)
for all experimental groups through the training set, fol-
lowed by the validation set and the testing set.
All ANN simulations were performed in the Matlab
Neural Network Toolbox, software version 4.0.2 (The
Mathworks, Inc., Natick, MA).
Three different simulations with different sets of input
parameters were performed using the same BPNN
architecture. For all simulations, the BPNN used six hid-
den layers and a sequential mode for training, while
keeping h = 0.4. The first simulation used a dataset con-
sisting of numerical normalized inputs of ADC, V and
PSA from days 0, 1 and 9, and categorical variables
representing treatment groups. The architecture, includ-
ing hidden layers, of the neural network is illustrated in
Figure 3. In the second simulation, the dataset consisted
of numerical K
trans, V and PSA values from days 0, 1
and 9, in addition to the treatment groups. The last
simulation included all numerical parameters (ADC,
K
trans, V and PSA) and treatment groups.
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Using a significance level of 5%, the Pearson’s correla-
tion test (SPSS 16.0, SPSS, Cary, NC) assessed whether
correlations between variables were significant.
Results
Ultimate treatment response was measured as tumor
volumes at day 30 (V30). Volumes of tumors in the
untreated group increased with 940 ± 91% compared to
baseline (day 0) volumes, whereas tumors receiving
radiation were 60 ± 25% larger at the endpoint than at
baseline. Androgen-deprivation alone resulted in reduc-
tion in tumor volumes by 40 ± 9% compared to base-
line, whereas tumors receiving combined androgen-
deprivation and radiotherapy presented a 64 ± 5%
tumor volume reduction at the experimental endpoint.
AB
CD
Figure 2 Input parameters to the artificial neural network model. Tumor volumes (V), prostate-specific antigen (PSA), the apparent diffusion
coefficients (ADC) and the vascular biomarker K
trans were acquired pre-treatment and early in treatment course and normalized to the baseline
(day 0) measurement. These parameters were used as inputs to the back propagation neural network (BPNN) in order to explore whether they
could predict therapeutic outcome, as measured by the 30 days post-radiotherapy (RT) tumor volumes.
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ing algorithm, 50% of the data were used for training, 25%
for validation and 25% for testing. The RMSE plot in Fig-
ure 4A shows the performance of the testing and valida-
tion of the first simulation, where normalized values of
ADC, PSA and tumor volumes from days 0, 1 and 9, in
addition to treatment groups (binary encoded), were used
as input variables. For this simulation, the RMSE increased
after 30 epochs, indicating overtraining. Thus, the optimal
training for the network was found to be 30 epochs. The
optimal number of epochs for the second and third simu-
lations was decided by a similar approach as above, and
found to be 49 and 69, respectively.
The use of ADC together with tumor volumes, PSA and
treatment groups as inputs to the BPNN model revealed a
correlation coefficient of 0.54 (p < 0.001) between pre-
dicted and measured treatment response (V30)( F i g u r e4 B ) .
By replacing the ADC with K
trans, the correlation coeffi-
cient increased to 0.66 (p < 0.001) (Figure 5). However,
the combination of all parameters (V, PSA, ADC, K
trans)
predicted treatment response with a correlation coefficient
of 0.85 (p < 0.001) between predicted and measured V30
(Figure 6). This approach was superior to all other ANN
simulations using the parameters independently.
Discussion
Assessment of therapeutic efficacy in PCa patients
represents a controversial issue in clinical medicine due
to the heterogeneity of the disease and its unpredictable
treatment response. Although the use of ADT and/or
Total input: 
I = w1X1 + …. + wnXn
where X1, ..., Xnare
measured inputs 
and w1, ..., wn
are weights
Output:
Y = f(I)
f
Ș
ij w
E new
ij ǻw = old
ij ǻw
෕
෕
-
2 M
1 = i
N
1 = j ij y - ij O
2
1
= E ෤෤ ¸
¹
· ¨
©
§
Forward propagation:  Backward propagation: 
f = activation 
function
Figure 3 Illustration of the architecture of the back propagation neural network (BPNN). The BPNN repeatedly adjusts the weights, w, of the
network and the threshold of each neuron (grey circles). The two steps of the learning process include forward propagation, where the predicted
output value, O, is compared to the actual output value, y, and backward propagation, where the error, E, from this comparison is back propagated
by updating the weights using a scaled conjugated gradient descent algorithm. The h (0 <h < 1) is a constant controlling the convergence rate of
the algorithm. A six-layered network approach and a sequential mode for training were used in all simulations, keeping h = 0.4.
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Figure 4 Prediction of treatment response using apparent diffusion coefficients from diffusion-weighted MRI. The root mean square
error (RMSE) plot visualizes the performance of the training, validation and test data (A). By using apparent diffusion coefficients (ADC), tumor
volumes (V), prostate-specific antigen (PSA) and treatment groups as inputs to the back propagation neural network (BPNN) a correlation
coefficient of 0.54 (p < 0.001) was found between predicted and measured treatment response (V30) (B).
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Figure 5 Prediction of treatment response using K
trans from
dynamic contrast-enhanced MRI. By using K
trans, tumor volumes
(V), prostate-specific antigen (PSA) and treatment groups as inputs
to the back propagation neural network (BPNN) a correlation
coefficient of 0.66 (p < 0.001) was found between predicted and
measured treatment response (V30).
Figure 6 Combining multiple functional MRI parameters
improves prediction of treatment response. By combining all
parameters (tumor volumes (V), prostate-specific antigen (PSA),
apparent diffusion coefficients (ADC), K
trans) and treatment groups,
the treatment response was predicted with a correlation coefficient
of 0.85 (p < 0.001) between predicted and measured V30.
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fails and high-risk patients usually present recurrent dis-
ease within few years. Classic prognostic factors, like
tumor volume, PSA, TNM classification and Gleason
score, are those that currently guide therapy selection.
However, these may be suboptimal in predicting out-
come for individual patients, as these factors are not
accounting for the underlying heterogeneity in vascular,
molecular and physiological processes causing large var-
iations in individual tumor responses. Thus, these fac-
tors may not enable prediction of treatment failure early
in the course of treatment, when therapeutic adjust-
ments still are feasible in terms of e.g. radiation dose
escalation or alterations in concurrent therapy.
T h eb e n e f i t so fA N N sc o m p a r e dt oc o n v e n t i o n a l
regression statistics comprise the capability of being
more accurate for large and complex data materials, e.g.
patient data with multiple parameters from multiple
measurement time-points. The artificial intelligence
models of biological systems can be generated without
needing assumptions about the underlying statistical dis-
tributions. Currently, in vivo imaging techniques are
rapidly evolving and being extensively tested for their
capability of correctly reflecting biological and physiolo-
gical properties of tumor tissue. Such functional infor-
mation is particularly beneficial for ANNs, since data
from multiple sources effectively can be incorporated
without needing knowledge on the combination of
underlying biological information.
The presented results were obtained in a preclinical
study in prostate cancer xenografts, and suggest that the
combination of functional MRI parameters, in addition
to standard clinical parameters, increases the power of
predicting therapeutic outcome in prostate carcinoma
a f t e rt r e a t m e n tw i t hA D Ta n d / o rR T .O u rt w of i r s t
simulations included each individual tumor’s ADC from
DWMRI, or K
trans from DCEMRI, respectively, in addi-
tion to the standard clinical parameters tumor volume
and PSA. The correlations between the BPNN predicted
and the measured treatment response were found to be
significant, but not very strong (R = 0.54 and R = 0.66,
respectively). When we combined both the ADC and
the K
trans results in the third simulation, this gave a con-
siderable increase in the correlation between the pre-
dicted and measured outcome (R = 0.85), indicating that
these parameters together reflect important treatment
response-related information of the tumors.
Our results were obtained in a human xenograft
model, thus, the next step could be to apply the same
approach in a clinical setting, including parameters from
functional MRI, as well as standard clinical parameters,
from PCa patients receiving ADT and/or RT treatment.
In the present study, the post-treatment imaging was
performed at day 1 and day 9, and these time-points are
maybe not easily translated into clinical assessment of
early treatment response. However, in recent years, the
use of imaging modalities for early-in-treatment
response assessments, for example 3 to 8 weeks after
initiation of therapy, has increased, and showed poten-
tial to evaluate whether the patient respond to the cho-
sen treatment or not. If this could be reliably measured,
or predicted, from this early imaging assessment, this
may help deciding whether the patient should receive
intensified, or altered treatment, or possibly a reduction
in unnecessary treatment. Moreover, if accounting for
the five times faster metabolism in mice, 9 days would
translate into approximately 6 weeks in a human, and
thus, this may be a relevant time-point for treatment
response evaluation, although not directly comparable.
H o w e v e r ,t h er e s u l t sf r o mt h ec u r r e n ts t u d ys u g g e s ta
promising additional utilization of the large amounts of
image data presently being acquired in hospitals. If the
model is validated in clinical data, the presented metho-
dology might become an early assay for treatment
response prediction, wherein different pre-treatment and
early in-treatment functional imaging parameters may
be combined with standard clinical parameters in order
to increase the prediction of how individual tumors
respond to therapy.
Although all simulations demonstrate significant cor-
relations between the predicted tumor volume 30 days
post-RT and the measured tumor volumes, Figures 4B,
5 and 6 also indicate a spread in the data points. This
implies that there is a probability of misclassifying the
response from individual tumors, meaning that precau-
tion should be taken if extrapolations to individuals are
performed uncritically. Further, when using a BPNN,
care should also be taken when training the network, in
order not to under- or overtrain it [25]. Since our
RMSE function (Figure 4A) from training, testing and
validating the network showed curve flattening after a
few training epochs, this indicated that no overtraining
occurred. However, if such a model is to be applied on
clinical data, the model must be rigorously validated, for
example with respect to the number of layers and
epochs. Patient materials will always present a larger
biological heterogeneity than xenografts grown in
immune-deficient mice, representing a risk for over-
training the network if the BPNN parameters are not
chosen cautiously.
Conclusion
The presented results, derived from a preclinical study in
prostate cancer xenografts, indicate that the combination
of several functional MRI parameters obtained pre-treat-
ment and early in the course of treatment, into an artifi-
cial neural network model, may provide additional, useful
information about therapy response. If clinically
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responding patients early during treatment course, allow-
ing these patients to be considered for alternative treat-
ment strategies, and, thus, providing a contribution to
the development of personalized prostate cancer therapy.
List of abbreviations
ADC: apparent diffusion coefficient; ADT: androgen-deprivation therapy;
ANN: artificial neural network; BPNN: back propagation neural network;
DCEMRI: dynamic contrast-enhanced magnetic resonance imaging; DWMRI:
diffusion-weighted magnetic resonance imaging; PCa: prostate cancer; PSA:
prostate specific antigen; RMSE: root mean square error; RT: radiotherapy; V:
volume
Acknowledgements
We thank Professor F. Saatcioglu at Department of Molecular Biosciences,
University of Oslo, for providing the CWR22 xenograft model, Professor E.
Paus and coworkers at the Central Laboratory, Department of Medical
Biochemistry, The Norwegian Radium Hospital, Oslo University Hospital, for
PSA analysis of blood samples, and department engineer Alexandr Kristian,
Department of Tumor Biology, Institute for Cancer Research, The Norwegian
Radium Hospital, Oslo University Hospital, for excellent assistance in animal
experiments.
Supported by the South-Eastern Norway Regional Health Authority (grant
2009070, to KR), the Norwegian Cancer Society (grant 80114001, to TS), and
the European Union 7th Framework Programme Grant 222741 - METOXIA.
Previous presentation: presented at the 21
st meeting of the European
Association for Cancer Research (EACR) in Oslo, June 26 - 29, 2010.
Author details
1Department of Radiation Biology, Institute for Cancer Research, The
Norwegian Radium Hospital, Oslo University Hospital, PO Box 4953 Nydalen,
0424 Oslo, Norway.
2Institute of Clinical Medicine, University of Oslo, Oslo,
Norway.
3Department of Oncology, Akershus University Hospital, Lorenskog,
Norway.
4University of Bergen, Bergen, Norway.
Authors’ contributions
KR designed the study, carried out the animal experiments, MRI data
acquisition and analysis, participated in ANN simulations and wrote the
manuscript. MK developed software and performed the ANN simulations,
and contributed in revision of the manuscript. TS and AHR helped in
discussion of the data and revision of the manuscript. DRO participated in
study design, data discussion and revision of the manuscript. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 1 February 2011 Accepted: 8 June 2011
Published: 8 June 2011
References
1. Mitchell RE, Chang SS: Current controversies in the treatment of high-risk
prostate cancer. Curr Opin Urol 2008, 18:263-268.
2. Barry MJ: Screening for prostate cancer–the controversy that refuses to
die. N Engl J Med 2009, 360:1351-1354.
3. Bammer R: Basic principles of diffusion-weighted imaging. Eur J Radiol
2003, 45:169-184.
4. Koh DM, Padhani AR: Diffusion-weighted MRI: a new functional clinical
technique for tumour imaging. Br J Radiol 2006, 79:633-635.
5. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV,
Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM:
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-
weighted MRI of a diffusable tracer: standardized quantities and
symbols. J Magn Reson Imaging 1999, 10:223-232.
6. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT: Dynamic contrast-
enhanced MRI as a predictor of tumour response to radiotherapy. Lancet
Oncol 2007, 8:63-74.
7. Seierstad T, Folkvord S, Røe K, Flatmark K, Skretting A, Olsen DR: Early
changes in apparent diffusion coefficient predict the quantitative
antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29
xenografts in athymic nude mice. Neoplasia 2007, 9:392-400.
8. Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J,
Gillies RJ, Stopeck A: Changes in water mobility measured by diffusion
MRI predict response of metastatic breast cancer to chemotherapy.
Neoplasia 2004, 6:831-837.
9. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q,
Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR,
Rehemtulla A, Ross BD: Functional diffusion map: a noninvasive MRI
biomarker for early stratification of clinical brain tumor response. Proc
Natl Acad Sci USA 2005, 102:5524-5529.
10. Cui Y, Zhang XP, Sun YS, Tang L, Shen L: Apparent diffusion coefficient:
potential imaging biomarker for prediction and early detection of
response to chemotherapy in hepatic metastases. Radiology 2008,
248:894-900.
11. Kakar M, Seierstad T, Røe K, Olsen DR: Artificial neural networks for
prediction of response to chemoradiation in HT29 xenografts. Int J
Radiat Oncol Biol Phys 2009, 75:506-511.
12. Kim CK, Park BK, Lee HM, Kim SS, Kim E: MRI techniques for prediction of
local tumor progression after high-intensity focused ultrasonic ablation
of prostate cancer. AJR Am J Roentgenol 2008, 190:1180-1186.
13. Kurhanewicz J, Vigneron D, Carroll P, Coakley F: Multiparametric magnetic
resonance imaging in prostate cancer: present and future. Curr Opin Urol
2008, 18:71-77.
14. Lisboa PJ, Taktak AF: The use of artificial neural networks in decision
support in cancer: a systematic review. Neural Netw 2006, 19:408-415.
15. Ramesh AN, Kambhampati C, Monson JR, Drew PJ: Artificial intelligence in
medicine. Ann R Coll Surg Engl 2004, 86:334-338.
16. Rumelhart DE, Hinton GE, Williams RJ: Learning representations by back-
propagating errors. Nature 1986, 323:533-536.
17. Gulliford SL, Webb S, Rowbottom CG, Corne DW, Dearnaley DP: Use of
artificial neural networks to predict biological outcomes for patients
receiving radical radiotherapy of the prostate. Radiother Oncol 2004,
71:3-12.
18. Gamito EJ, Crawford ED: Artificial neural networks for predictive
modeling in prostate cancer. Curr Oncol Rep 2004, 6:216-221.
19. Tewari A, Issa M, El-Galley R, Stricker H, Peabody J, Pow-Sang J, Shukla A,
Waisman Z, Rubin M, Wei J, Montie J, Demers R, Johnson CC, Lamerato L,
Divine GW, Crawford ED, Gamito EJ, Farah R, Naravan P, Carlson G,
Menon M: Genetic adaptive neural network to predict biochemical
failure after radical prostatectomy: a multi-institutional study. Mol Urol
2001, 5:163-169.
20. Finne P, Finne R, Auvinen A, Juusela H, Aro J, Määttänen L, Hakama M,
Rannikko S, Tammela TL, Stenman U: Predicting the outcome of prostate
biopsy in screen-positive men by a multilayer perceptron network.
Urology 2000, 56:418-422.
21. Stephan C, Kahrs AM, Cammann H, Lein M, Schrader M, Deger S, Miller K,
Jung K: A [-2]proPSA-based artificial neural network significantly
improves differentiation between prostate cancer and benign prostatic
diseases. Prostate 2009, 69:198-207.
22. Røe K, Seierstad T, Kristian A, Mikalsen LT, Mælandsmo GM, van der
Kogel AJ, Ree AH, Olsen DR: Longitudinal magnetic resonance imaging-
based assessment of vascular changes and radiation response in
androgen-sensitive prostate carcinoma xenografts under androgen-
exposed and androgen-deprived conditions. Neoplasia 2010, 12:818-825.
23. Seierstad T, Røe K, Høvik B: Construction of a modified capacitive overlap
MR coil for imaging of small animals and objects in a clinical whole-
body scanner. Phys Med Biol 2007, 52:N513-N522.
24. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J:
Method for the quantitative assessment of contrast agent uptake in
dynamic contrast-enhanced MRI. Magn Reson Med 1994, 31:567-571.
25. Geman S, Bienenstock E, Doursat R: Neural networks and the bias/
variance dilemma. Neural Comput 1992, 4:1-58.
doi:10.1186/1748-717X-6-65
Cite this article as: Røe et al.: Early prediction of response to
radiotherapy and androgen-deprivation therapy in prostate cancer by
repeated functional MRI: a preclinical study. Radiation Oncology 2011
6:65.
Røe et al. Radiation Oncology 2011, 6:65
http://www.ro-journal.com/content/6/1/65
Page 9 of 9